anti-coagulation effect of aspirin, LMWH and rivaroxaban after total hip arthroplasty:a prospective randomised control trial

Administering aspirin and rivaroxaban to prevent deep venous thrombosis after total hip arthroplasty: a prospective randomised control trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800016829

Enrollment

Unknown

Registered

2018-06-27

Start date

2018-06-30

Completion date

Unknown

Last updated

2018-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

arthroplasty

Interventions

A:aspirin

B:LMWH

C:rivaroxaban

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: patients who undergo unilateral total hip arthroplasty for osteoarthritis; patients who are willing to participate this study and sign up the informed consent form

Exclusion criteria

Exclusion criteria: patients who had a history of hemorrhagic disease or a bleeding tendency during the preoperative coagulation test, had a medical history of VTE or lower limb artherosclerosis, or used a combination of other drugs that might impact the findings

Design outcomes

Primary

Measure	Time frame
PT APTT INR factor X antibody;DVT;complication;function;	—

Countries

China

Contacts

Public ContactZhou Zongke

Department of Orthopaedic Surgery, West China Hospital, West China Medical School, Sichuan University

zongke@126.com+86 18980601028

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026